Updates - Page 5
Covid-19 action plan – A message to our customers, collaboration partners & colleagues
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…
Read update
NB win Phase II of CRACK IT Challenge 29: ImmuLiver
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to…
Read update
NB hiPSC lung models; Valuable tools in understanding health impacts of air pollution
In 2014, the World Health Organisation (WHO) estimated that air pollution leads to 7 million deaths per year. This figure is more than the number of deaths from…
Read update
Newcells Biotech acquires IP for retinal organoids
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal org
Read update
Vision for the future of childhood retinal dystrophies
The retina is the means through which most people primarily perceive the world and for children particularly, visual defects can affect educational, social and emotional development.1 The importance of retinal…
Read update
NB RPE model to improve drug retinal toxicity assessment
Retinal toxicity is an adverse side effect that can cause (usually irreversible) deterioration of a person’s vision, when taking certain medication. This has…
Read update
Dr Frank Armstrong appointed as Non-executive Director
Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and…
Read update
iPSC derived retinal organoids: A promising tool for modelling retinitis pigmentosa
Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin
Read update
Newcells Biotech technology: the fight against antibacterial resistance
Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the…
Read updateWHY WE DO IT
Our purpose is to bridge the gap between scientific discovery and patients. We make a difference by providing better predictions of clinical outcomes.
Read updateNB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding
Newcells Biotech are one…
Read updateWHO WE ARE
A passionate, rigorous and dedicated team of scientists who deliver the highest quality services and products. Your reliable and knowledgeable partner.
Read update
